Jennifer Fagan

Jennifer Fagan serves as a key procurement professional within the Contract Administration Services Division of the Department of Homeland Security’s Office of Procurement Operations, where she manages the acquisition of critical biological product manufacturing capabilities essential to national security and operational readiness. Her role centers on overseeing the full lifecycle of contracts for research, development, and production of non-diagnostic biological products, ensuring compliance with federal acquisition regulations and aligning procurements with DHS’s mission to safeguard public health and biodefense infrastructure. She handles complex, high-stakes solicitations requiring rigorous technical evaluation, risk mitigation, and supply chain integrity, primarily supporting scientific and engineering programs that enhance the nation’s biological threat response capacity. Fagan maintains strategic relationships with a select group of specialized manufacturers and contract research organizations with proven expertise in GMP-compliant biological production, sterile processing, and biosafety level 3 containment systems. While no single contractor dominates her portfolio, her procurement patterns reflect consistent engagement with firms possessing advanced biomanufacturing certifications, cGMP validation experience, and federal supply chain security credentials. Her working relationships are characterized by collaborative pre-solicitation engagement, transparent evaluation criteria, and performance-based contract management to ensure technical fidelity and mission-critical delivery. Fagan’s contracting activity reflects a strict preference for unrestricted competition, with 100% of her acquisitions issued under the “No Set-Aside” classification. This approach prioritizes technical capability, scalability, and national security imperatives over socioeconomic set-asides, indicating a focus on mission-critical outcomes rather than socioeconomic targets. While small business participation is not formally incentivized in her portfolio, her process remains fully compliant with all federal procurement statutes and emphasizes merit-based selection. Her primary NAICS focus is 325414—Biological Product (except Diagnostic) Manufacturing—reflecting deep expertise in procuring vaccines, therapeutics, and biologics for defense and emergency response applications. She specializes in acquisitions involving cell culture systems, lyophilization, cold chain logistics, and biosafety-compliant manufacturing facilities, demonstrating advanced technical fluency in biopharmaceutical production and federal biodefense supply chain requirements.